Innate Pharma S.A.
NASDAQ:IPHABiotechnology
+$0.03 today
- Market cap
- $139.83M
- Beta
- 0.89
- P/E (TTM)
- -3.0
- EPS (TTM)
- -$0.54
Volume 0.09M
Average 0.07M
IPHA Research & Development
Spending on developing new products, technologies, and improvements to existing offerings.
Innate Pharma S.A.NASDAQ: IPHA
Research & Development · Q4 FY2025 · quarter ended Dec 2025
Research & development grows 0.1% year over year
Q4 FY2025 research & development of €22.93M rose 0.1% year over year. Over 3 fiscal years it compounded at -5.5% a year.
Context
- Research & development amounted to 1565.1% of revenue in FY2025, up 1153.3 pp from a year earlier.
- Research & development increased in 1 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
Sources:Income StatementText generated from reported figures; not investment advice.
Research & Development history
EUR · from the income statement
- Latest · FY2025
- 43.62M EUR
- Year-over-year change
- -16.1%
- 4-year CAGR
- -1.9%
| Period | Period end | Research & Development | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 43.62M | -16.1% |
| FY2024 | 2024-12-31 | 51.98M | -7.2% |
| FY2023 | 2023-12-31 | 56.02M | +8.4% |
| FY2022 | 2022-12-31 | 51.66M | +9.9% |
| FY2021 | 2021-12-31 | 47M | — |
Research & Development vs competitors
How IPHA compares with its peers on the latest reported figures
- Peers report in different currencies, so research & development is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -16.1% is the 6th highest of 9, against a peer median of -1.4%.
- Research & development amounts to 1565.1% of revenue for IPHA, versus a peer median of 760.8%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $74.27M USD | +76.4% | +63.2% | — | |
| LTM Mar 2026 | CHF 46.97M CHF | -1.7% | -7.5% | — | |
| FY2025 | €43.62M EUR | -16.1% | -5.5% | 1565.1% | |
| LTM Mar 2026 | $31.62M USD | -19.6% | +9.2% | 6022.3% | |
| LTM Mar 2026 | $23.92M USD | -1.0% | -9.4% | 32.9% | |
ELTXElicio Therapeutics, Inc. | LTM Mar 2026 | $23.84M USD | -29.5% | +13.5% | — |
| LTM Mar 2026 | $18.8M USD | -26.8% | -18.0% | 593.1% | |
| LTM Mar 2026 | $18.58M USD | +33.3% | +11.1% | — | |
| LTM Mar 2026 | $16.56M USD | +5.5% | -23.1% | 928.4% | |
| Peer median (excluding IPHA) | — | -1.4% | +0.9% | 760.8% | |
Competitors are the stored peer set for IPHA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 12.11M | 57.67M | 51.9M | 12.62M | 2.79M |
| Cost of Revenue | 47M | 51.66M | 56.02M | 51.98M | 0 |
| Gross Profit | (22.3M) | 6.01M | 5.62M | 12.62M | 2.79M |
| Gross Margin | -184.1% | 10.4% | 10.8% | 100.0% | 100.0% |
| Research & Development | 47M | 51.66M | 56.02M | 51.98M | 43.62M |
| Selling, General & Admin | 25.52M | 14.47M | 11.75M | 11.93M | 11M |
| Operating Expenses | 25.52M | 63.44M | 18.29M | 64.2M | 56.21M |
| Depreciation & Amortization | 4.6M | 45.41M | 5.09M | 1.99M | 5.09M |
| EBITDA | (43.23M) | (12.28M) | (1.84M) | (46.91M) | (43.65M) |
| EBITDA Margin | -356.9% | -21.3% | -3.5% | -371.7% | -1566.1% |
| Operating Income | (47.83M) | (57.43M) | (12.67M) | (51.58M) | (53.43M) |
| Operating Margin | -394.9% | -99.6% | -24.4% | -408.6% | -1916.9% |
| Interest Income | 327K | 546K | 3.18M | 2.44M | 1.32M |
| Interest Expense | 312K | 288K | 640K | 566K | 440K |
| Other Income / Expenses | 2.35M | (547K) | 5.1M | 2.1M | 4.25M |
| Income Before Tax | (45.48M) | (57.97M) | (7.57M) | (49.47M) | (49.18M) |
| Pre-Tax Margin | -375.5% | -100.5% | -14.6% | -392.0% | -1764.5% |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (52.81M) | (58.1M) | (7.57M) | (49.47M) | (49.18M) |
| Net Margin | -436.0% | -100.7% | -14.6% | -392.0% | -1764.5% |
| EPS (Basic) | (0.57) | (0.73) | (0.09) | (0.61) | (0.53) |
| EPS (Diluted) | (0.57) | (0.73) | (0.09) | (0.61) | (0.53) |
| Weighted Avg Shares | 79.54M | 79.59M | 84.11M | 81.05M | 89.42M |
| Weighted Avg Shares (Diluted) | 79.54M | 79.64M | 84.11M | 81.05M | 89.42M |
Innate Pharma S.A.
NASDAQ:IPHA
Intrinsic Alpha fair value
Locked
Current Price
$1.33
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.